HK1171027A1 - Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof hiv - Google Patents

Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof hiv

Info

Publication number
HK1171027A1
HK1171027A1 HK12111361.4A HK12111361A HK1171027A1 HK 1171027 A1 HK1171027 A1 HK 1171027A1 HK 12111361 A HK12111361 A HK 12111361A HK 1171027 A1 HK1171027 A1 HK 1171027A1
Authority
HK
Hong Kong
Prior art keywords
hiv
regulatory
peptides
utilization
compositions
Prior art date
Application number
HK12111361.4A
Other languages
English (en)
Chinese (zh)
Inventor
格雷戈里．艾倫．斯特洛夫
威爾遜．羅梅羅．卡帕羅斯-萬德雷
Original Assignee
派特塞爾有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by 派特塞爾有限公司 filed Critical 派特塞爾有限公司
Publication of HK1171027A1 publication Critical patent/HK1171027A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK12111361.4A 2006-03-10 2012-11-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof hiv HK1171027A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
HK1171027A1 true HK1171027A1 (en) 2013-03-15

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111361.4A HK1171027A1 (en) 2006-03-10 2012-11-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof hiv

Country Status (21)

Country Link
US (4) US20100055119A1 (ru)
EP (2) EP2392587B1 (ru)
JP (3) JP2009529570A (ru)
KR (1) KR20080106467A (ru)
CN (2) CN102443052B (ru)
AP (2) AP2015008680A0 (ru)
AU (1) AU2007226430B2 (ru)
BR (1) BRPI0708708A2 (ru)
CA (1) CA2645342A1 (ru)
DK (2) DK2392587T3 (ru)
EA (1) EA019733B1 (ru)
ES (2) ES2616341T3 (ru)
HK (1) HK1171027A1 (ru)
IL (2) IL193965A0 (ru)
MX (1) MX2008011520A (ru)
NO (1) NO20083576L (ru)
NZ (1) NZ570708A (ru)
PL (1) PL2392587T3 (ru)
SG (1) SG170092A1 (ru)
UA (1) UA97800C2 (ru)
WO (1) WO2007104932A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2015082724A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
DE69416824T2 (de) 1993-10-14 1999-07-08 Seikagaku Corp., Tokio/Tokyo Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
CA2173138A1 (en) 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
IL132998A0 (en) * 1997-05-20 2001-03-19 St Luke S Roosevelt Hospital Vif-derived hiv protease inhibitors
WO1999013896A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Attenuated vif dna immunization cassettes for genetic vaccines
US6492110B1 (en) 1998-11-02 2002-12-10 Uab Research Foundation Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
EP1155035A2 (de) * 1999-02-19 2001-11-21 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2386499A1 (en) * 1999-10-05 2001-04-12 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
JP2003523365A (ja) 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
CA2425152A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
CA2439990A1 (en) * 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2004031345A2 (en) 2002-05-20 2004-04-15 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
JP4773352B2 (ja) * 2003-09-17 2011-09-14 デューク ユニバーシティ コンセンサス／先祖免疫原
EP1778282B1 (en) * 2004-08-17 2016-03-30 Institut Gustave Roussy Mutated hiv nef for modulating immunity
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗

Also Published As

Publication number Publication date
EA019733B1 (ru) 2014-05-30
AP3642A (en) 2016-03-16
BRPI0708708A2 (pt) 2011-06-07
KR20080106467A (ko) 2008-12-05
EP2004676B1 (en) 2016-11-16
CN104558126B (zh) 2020-02-14
US20170281750A1 (en) 2017-10-05
AU2007226430B2 (en) 2013-08-29
AU2007226430A1 (en) 2007-09-20
EP2392587A1 (en) 2011-12-07
MX2008011520A (es) 2009-01-07
US20130039937A1 (en) 2013-02-14
ES2616341T3 (es) 2017-06-12
NZ570708A (en) 2011-12-22
WO2007104932A3 (en) 2007-11-22
AU2007226430A2 (en) 2008-10-09
CA2645342A1 (en) 2007-09-20
JP2013040172A (ja) 2013-02-28
US9675686B2 (en) 2017-06-13
JP2015007069A (ja) 2015-01-15
NO20083576L (no) 2008-12-10
US20150182618A1 (en) 2015-07-02
PL2392587T3 (pl) 2016-08-31
SG170092A1 (en) 2011-04-29
AP2008004609A0 (en) 2008-10-31
WO2007104932A2 (en) 2007-09-20
UA97800C2 (ru) 2012-03-26
CN102443052B (zh) 2014-12-31
EP2004676A2 (en) 2008-12-24
AP2015008680A0 (en) 2015-08-31
ES2573105T3 (es) 2016-06-06
DK2004676T3 (en) 2017-02-20
US10034933B2 (en) 2018-07-31
JP6422698B2 (ja) 2018-11-14
US8992934B2 (en) 2015-03-31
EA200870342A1 (ru) 2009-02-27
US20100055119A1 (en) 2010-03-04
JP2009529570A (ja) 2009-08-20
EP2392587B1 (en) 2016-05-04
IL219544A0 (en) 2012-06-28
IL193965A0 (en) 2011-08-01
CN102443052A (zh) 2012-05-09
DK2392587T3 (en) 2016-05-23
CN104558126A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
HK1221252A1 (zh) 限制的 肽及含有其的藥物組合物
IL195580A (en) L – fkbp polypeptides, preparations containing them, methods of preparation and use
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
HK1127877A1 (en) Composition containing peptide as the active ingredient
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL215603A0 (en) Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
PL1913138T3 (pl) Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
IL185308A0 (en) Replikin peptides and uses thereof
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
AP2008004512A0 (en) Bacteriocion inducer peptides
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
IL213026A0 (en) TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
HK1171027A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof hiv
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
EP1910405A4 (en) PEPTIDES DERIVED FROM COMPLEMENT C3A AND APPLICATIONS THEREOF
IL205405A0 (en) Polypeptide compound, composition comprising the same and use thereof
IL192800A0 (en) Fgf2-binding peptides and uses thereof
GB0612917D0 (en) Metallic compositions,preparations and uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190309